NYSE:GENGenesis Healthcare Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genesis Healthcare Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.90 +0.01 (+1.12 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$0.89Now: $0.90▼$0.9350-Day Range$0.59MA: $0.82▼$1.1652-Week Range$0.58Now: $0.90▼$1.86Volume931,894 shsAverage Volume582,408 shsMarket Capitalization$148.92 millionP/E Ratio2.44Dividend YieldN/ABeta1.31 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services, Rehabilitation Therapy Services, and All Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of December 31, 2018, it provided inpatient services through a network of 425 skilled nursing and assisted/senior living facilities, including 399 skilled nursing facilities and 26 stand-alone assisted/senior living facilities across 29 states. Genesis HealthCare, Inc. also supplies rehabilitation and respiratory therapy to approximately 1,400 healthcare locations in 46 states and the District of Columbia. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Genesis Healthcare. Previous Next 2.7 Community Rank Outperform VotesGenesis Healthcare has received 455 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGenesis Healthcare has received 388 “underperform” votes. (Add your “underperform” vote.)Community SentimentGenesis Healthcare has received 53.97% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Genesis Healthcare and other stocks. Vote “Outperform” if you believe GEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGenesis Healthcare does not currently pay a dividend.Dividend GrowthGenesis Healthcare does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genesis Healthcare insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $71,759.00 in company stock.Percentage Held by Insiders35.20% of the stock of Genesis Healthcare is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.94% of the stock of Genesis Healthcare is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Genesis Healthcare is 2.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Genesis Healthcare is 2.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.75. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.99 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Skilled nursing care facilities Sub-IndustryN/A SectorMedical Current SymbolNYSE:GEN Previous SymbolNYSE:SKH CUSIPN/A CIK1351051 Webwww.genesishcc.com Phone610-444-6350Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.79Price-To-Earnings Trailing P/E Ratio2.44 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.57 billion Price / Sales0.03 Cash Flow$0.79 per share Price / Cash Flow1.14 Book Value($6.57) per share Price / Book-0.14Profitability EPS (Most Recent Fiscal Year)$0.10 Net Income$14.62 million Net Margins1.41% Return on Equity-6.57% Return on Assets1.54%Miscellaneous Employees55,000 Outstanding Shares164,809,000Market Cap$148.92 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable GEN Rates by TradingView Receive GEN News and Ratings via Email Sign-up to receive the latest news and ratings for GEN and its competitors with MarketBeat's FREE daily newsletter. Genesis Healthcare (NYSE:GEN) Frequently Asked Questions How has Genesis Healthcare's stock been impacted by COVID-19 (Coronavirus)? Genesis Healthcare's stock was trading at $1.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GEN stock has decreased by 21.8% and is now trading at $0.9077. View which stocks have been most impacted by Coronavirus. When is Genesis Healthcare's next earnings date? Genesis Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Genesis Healthcare. How were Genesis Healthcare's earnings last quarter? Genesis Healthcare Inc (NYSE:GEN) announced its quarterly earnings results on Wednesday, May, 27th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of ($0.02) by $0.26. The firm had revenue of $1.09 billion for the quarter. Genesis Healthcare had a negative return on equity of 6.57% and a net margin of 1.41%. View Genesis Healthcare's earnings history. Has Genesis Healthcare been receiving favorable news coverage? Headlines about GEN stock have trended positive on Friday, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genesis Healthcare earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutGenesis Healthcare. Are investors shorting Genesis Healthcare? Genesis Healthcare saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,300,000 shares, an increase of 8.0% from the April 30th total of 2,130,000 shares. Based on an average daily trading volume, of 393,000 shares, the days-to-cover ratio is presently 5.9 days. Approximately 4.2% of the company's shares are short sold. View Genesis Healthcare's Current Options Chain. Who are some of Genesis Healthcare's key competitors? Some companies that are related to Genesis Healthcare include Castle Biosciences (CSTL), DiaMedica Therapeutics (DMCAF), Atara Biotherapeutics (ATRA), Ardelyx (ARDX), DBV TECHNOLOGIE/S (DBVT), Trillium Therapeutics (TRIL), Bellus Health (BLU), HLS Therapeutics (HLS), Syndax Pharmaceuticals (SNDX), Draegerwerk AG & Co KGaA (DRW3), CEL-SCI (CVM), Oxford BioMedica (OXB), 111 (YI), Dynavax Technologies (DVAX) and GenMark Diagnostics (GNMK). View all competitors. What other stocks do shareholders of Genesis Healthcare own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genesis Healthcare investors own include Flaherty&Crumrine Prfrd Scts Incm Fd (FFC), Vaxart (VXRT), Advanced Micro Devices (AMD), Amarin (AMRN), Anavex Life Sciences (AVXL), Agile Therapeutics (AGRX), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Aduro BioTech (ADRO) and Gilead Sciences (GILD). Who are Genesis Healthcare's key executives? Genesis Healthcare's management team includes the following people: Mr. George V. Hager Jr., CEO & Director (Age 63)Mr. Thomas DiVittorio, CFO, Exec. VP, Treasurer & Assistant Sec. (Age 51)Mr. Paul David Bach, COO & Exec. VP (Age 60)Dr. JoAnne Susan Reifsnyder Ph.D., MSN, MBA, FAAN, Exec. VP of Clinical Operations & Chief Nursing Officer (Age 60)Mr. Richard L. Castor, Chief Information Officer & Sr. VP (Age 64) What is Genesis Healthcare's stock symbol? Genesis Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "GEN." Who are Genesis Healthcare's major shareholders? Genesis Healthcare's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.74%), First Washington CORP (2.18%), Acadian Asset Management LLC (0.99%), State Street Corp (0.79%), Geode Capital Management LLC (0.48%) and Nuveen Asset Management LLC (0.35%). Company insiders that own Genesis Healthcare stock include David A Reis, George V Hager, Jr, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young and Thomas Divittorio. View institutional ownership trends for Genesis Healthcare. Which institutional investors are selling Genesis Healthcare stock? GEN stock was sold by a variety of institutional investors in the last quarter, including First Washington CORP, BlackRock Inc., JPMorgan Chase & Co., UBS Group AG, and Nuveen Asset Management LLC. Company insiders that have sold Genesis Healthcare company stock in the last year include George V Hager, Jr, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young, and Thomas Divittorio. View insider buying and selling activity for Genesis Healthcare. Which institutional investors are buying Genesis Healthcare stock? GEN stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, State Street Corp, SG Americas Securities LLC, Connor Clark & Lunn Investment Management Ltd., Wells Fargo & Company MN, and Acadian Asset Management LLC. View insider buying and selling activity for Genesis Healthcare. How do I buy shares of Genesis Healthcare? Shares of GEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Genesis Healthcare's stock price today? One share of GEN stock can currently be purchased for approximately $0.91. How big of a company is Genesis Healthcare? Genesis Healthcare has a market capitalization of $149.60 million and generates $4.57 billion in revenue each year. The company earns $14.62 million in net income (profit) each year or $0.10 on an earnings per share basis. Genesis Healthcare employs 55,000 workers across the globe. What is Genesis Healthcare's official website? The official website for Genesis Healthcare is www.genesishcc.com. How can I contact Genesis Healthcare? Genesis Healthcare's mailing address is 101 EAST STATE STREET, KENNETT SQUARE PA, 19348. The company can be reached via phone at 610-444-6350 or via email at [email protected] This page was last updated on 6/5/2020 by MarketBeat.com Staff
